These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2960 related items for PubMed ID: 20129555

  • 1. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H, Maehara A, Mintz GS, Yu A, Wang H, Mandinov L, Popma JJ, Ellis SG, Grube E, Dawkins KD, Weissman NJ, Turco MA, Ormiston JA, Stone GW.
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [Abstract] [Full Text] [Related]

  • 2. Long-term impact of routinely detected early and late incomplete stent apposition: an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies.
    Steinberg DH, Mintz GS, Mandinov L, Yu A, Ellis SG, Grube E, Dawkins KD, Ormiston J, Turco MA, Stone GW, Weissman NJ.
    JACC Cardiovasc Interv; 2010 May; 3(5):486-94. PubMed ID: 20488404
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DS, TAXUS IV Investigators.
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [Abstract] [Full Text] [Related]

  • 4. Impact of in-stent minimal lumen area at 9 months poststent implantation on 3-year target lesion revascularization-free survival: a serial intravascular ultrasound analysis from the TAXUS IV, V, and VI trials.
    Doi H, Maehara A, Mintz GS, Weissman NJ, Yu A, Wang H, Mandinov L, Popma JJ, Ellis SG, Grube E, Dawkins KD, Stone GW.
    Circ Cardiovasc Interv; 2008 Oct; 1(2):111-8. PubMed ID: 20031665
    [Abstract] [Full Text] [Related]

  • 5. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG, Kang SJ, Ahn JM, Kim WJ, Lee JY, Park DW, Lee SW, Kim YH, Lee CW, Park SW, Park SJ.
    Catheter Cardiovasc Interv; 2014 May 01; 83(6):873-8. PubMed ID: 22815193
    [Abstract] [Full Text] [Related]

  • 6. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program.
    Stone GW, Ellis SG, Colombo A, Grube E, Popma JJ, Uchida T, Bleuit JS, Dawkins KD, Russell ME.
    JACC Cardiovasc Interv; 2011 May 01; 4(5):530-42. PubMed ID: 21596326
    [Abstract] [Full Text] [Related]

  • 7. Angiographic and intravascular ultrasound follow up of paclitaxel- and sirolimus-eluting stent after poststent high-pressure balloon dilation: from the poststent optimal stent expansion trial.
    Park SM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y, Kang WC, Ahn T, Kim BK, Oh SJ, Jeon DW, Yang JY.
    Catheter Cardiovasc Interv; 2011 Jan 01; 77(1):15-21. PubMed ID: 20928842
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C, Magro M, Boersma E, Onuma Y, Nauta ST, Gaspersz MP, van der Giessen WJ, van Domburg RT, Serruys PW, Interventional Cardiologists of the Thoraxcenter.
    JACC Cardiovasc Interv; 2010 Oct 01; 3(10):1051-8. PubMed ID: 20965464
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
    Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, White R, Cao S, Sudhir K, Stone GW.
    Catheter Cardiovasc Interv; 2009 Nov 01; 74(5):719-27. PubMed ID: 19530147
    [Abstract] [Full Text] [Related]

  • 15. Vascular responses to the multiple overlapped paclitaxel-eluting stents for the treatment of bare-metal in-stent restenotic lesions: angiographic and intravascular ultrasound analysis from the TAXUS-V ISR trial.
    Koizumi T, Fitzgerald PJ, Honda Y, Ellis SG, Kent K, Martin SL, Brown CL, Masud AR, Patterson JB, Greenberg J, Friedman M, Uchida T, Stone GW.
    Cardiovasc Revasc Med; 2010 Nov 01; 11(3):140-8. PubMed ID: 20599163
    [Abstract] [Full Text] [Related]

  • 16. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR, Belkacemi A, Dubois C, Nathoe H, Dens J, Naber C, Adriaenssens T, van Belle E, Doevendans P, Agostoni P.
    Catheter Cardiovasc Interv; 2012 Dec 01; 80(7):1138-46. PubMed ID: 22422607
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 148.